Aarti Drugs Limited (IN:AARTIDRUGS)
:AARTIDRUGS
Top Page
Aarti Drugs Limited
(AARTIDRUGS)
Select Model
Select Model
Rating:57Neutral
Price Target:
₹364.00
▼(-10.08% Downside)
Action:ReiteratedDate:11/30/25
Aarti Drugs Limited's overall stock score is influenced primarily by its stable financial performance, despite some challenges in revenue growth and cash flow management. Technical analysis indicates bearish momentum, with the stock trading below key moving averages and oversold conditions. Valuation metrics suggest the stock is fairly valued, but with a low dividend yield. These factors collectively result in a cautious outlook.
Positive Factors
Integrated API & Specialty Chemicals Model
Aarti Drugs’ core business producing APIs, intermediates and specialty chemicals is a durable B2B model. Supplying both domestic and export markets provides structural demand diversification. Long product life cycles and regulatory approvals create high switching costs for customers and steady baseline volumes.
Negative Factors
Recent Revenue Decline
A decline in the most recent year signals structural demand or competitive pressure that could compress scale benefits. Sustained revenue weakness limits reinvestment capacity, raises per-unit costs as utilization falls, and challenges long-term margin expansion unless growth drivers are restored.
Read all positive and negative factors
Positive Factors
Negative Factors
Integrated API & Specialty Chemicals Model
Aarti Drugs’ core business producing APIs, intermediates and specialty chemicals is a durable B2B model. Supplying both domestic and export markets provides structural demand diversification. Long product life cycles and regulatory approvals create high switching costs for customers and steady baseline volumes.
Read all positive factors
Aarti Drugs Limited (AARTIDRUGS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹32.13B
Dividend Yield0.24%
Average Volume (3M)11.99K
Price to Earnings (P/E)23.2
Beta (1Y)1.09
Revenue Growth4.08%
EPS Growth31.52%
CountryIN
Employees1,064
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)4.40
Shares Outstanding91,270,000
10 Day Avg. Volume14,342
30 Day Avg. Volume11,994
Financial Highlights & Ratios
PEG Ratio-16.53
Price to Book (P/B)2.30
Price to Sales (P/S)1.32
P/FCF Ratio46.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹480.00Price Target Upside18.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)28.2
Revenue Forecast (FY)₹29.47B
Aarti Drugs Limited Business Overview & Revenue Model
Company Description
Aarti Drugs Limited, through its subsidiaries, engages in the pharmaceuticals business in India and internationally. The company offers active pharmaceutical ingredients in various therapeutic categories, including anti-inflammatory, cardioprotect...
How the Company Makes Money
Aarti Drugs primarily makes money by manufacturing and selling (1) APIs and (2) pharmaceutical intermediates/specialty chemicals to customers that use these materials as inputs for finished drug formulations or chemical products. Revenue is genera...
Aarti Drugs Limited Financial Statement Overview
Summary
Income Statement
75
Positive
Balance Sheet
70
Positive
Cash Flow
68
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 24.77B | 23.87B | 25.29B | 27.16B | 24.89B | 21.55B |
| Gross Profit | 9.07B | 8.45B | 8.51B | 3.69B | 3.89B | 6.00B |
| EBITDA | 3.27B | 2.87B | 3.25B | 3.12B | 3.44B | 4.42B |
| Net Income | 1.99B | 1.68B | 1.71B | 1.66B | 2.05B | 2.80B |
Balance Sheet | ||||||
| Total Assets | 26.12B | 25.75B | 24.32B | 24.21B | 22.08B | 17.66B |
| Cash, Cash Equivalents and Short-Term Investments | 245.40M | 226.10M | 89.28M | 211.70M | 343.81M | 219.84M |
| Total Debt | 5.73B | 6.15B | 5.64B | 6.09B | 5.43B | 3.51B |
| Total Liabilities | 11.44B | 12.05B | 11.50B | 12.29B | 11.72B | 8.53B |
| Stockholders Equity | 14.68B | 13.69B | 12.82B | 11.92B | 10.36B | 9.13B |
Cash Flow | ||||||
| Free Cash Flow | 580.50M | 674.20M | 1.33B | -304.70M | -823.39M | 667.19M |
| Operating Cash Flow | 1.52B | 2.45B | 3.59B | 1.34B | 696.36M | 1.55B |
| Investing Cash Flow | -940.60M | -1.65B | -2.24B | -1.64B | -1.49B | -716.79M |
| Financing Cash Flow | -562.20M | -821.20M | -1.36B | 165.40M | 920.25M | -811.29M |
Aarti Drugs Limited Technical Analysis
Neutral
404.80
Price Trends
361.51
Negative
389.61
Negative
439.88
Negative
Market Momentum
-7.53
Negative
51.52
Neutral
57.18
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:AARTIDRUGS, the sentiment is Neutral. The current price of 404.8 is above the 20-day moving average (MA) of 344.23, above the 50-day MA of 361.51, and below the 200-day MA of 439.88, indicating a neutral trend. The MACD of -7.53 indicates Negative momentum. The RSI at 51.52 is Neutral, neither overbought nor oversold. The STOCH value of 57.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:AARTIDRUGS.
Aarti Drugs Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | ₹775.92B | 18.87 | ― | 0.33% | 7.33% | -3.79% | |
73 Outperform | ₹376.92B | 27.58 | ― | 0.28% | 9.66% | 25.79% | |
70 Outperform | ₹1.02T | 21.88 | ― | 0.63% | 14.10% | 9.72% | |
68 Neutral | ₹964.01B | 45.14 | ― | 0.87% | 6.93% | 21.55% | |
57 Neutral | ₹32.13B | 23.17 | ― | 0.24% | 4.08% | 31.52% | |
53 Neutral | ₹591.01B | 35.61 | ― | 0.24% | 30.27% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:AARTIDRUGS
Aarti Drugs Limited
352.05
20.98
6.34%
IN:AUROPHARMA
Aurobindo Pharma Ltd
1,335.95
235.28
21.38%
IN:CIPLA
Cipla Ltd
1,193.40
-207.18
-14.79%
IN:DRREDDY
Dr. Reddy's Laboratories Ltd.
1,217.60
114.84
10.41%
IN:GLENMARK
Glenmark Pharmaceuticals Limited
2,094.30
598.82
40.04%
IN:IPCALAB
IPCA Laboratories Limited
1,485.95
87.79
6.28%
Aarti Drugs Limited Corporate Events
Aarti Drugs Injects Rs 10 Crore into Subsidiary Pinnacle Life Science for Expansion
Mar 7, 2026
Aarti Drugs Limited has approved an investment of up to Rs 10 crore in equity shares of its wholly owned subsidiary, Pinnacle Life Science Private Limited, via a rights issue, with shares to be allotted on or before March 20, 2026. The cash infusi...
Aarti Drugs Schedules Investor Meetings at Mumbai Conference
Mar 4, 2026
Aarti Drugs Limited has announced that its officials will participate in an investor conference organized by Investec on March 11, 2026, at Trident BKC in Mumbai, holding one-on-one and group meetings with analysts and institutional investors. The...
Aarti Drugs Deepens Latin American Push with New Chilean Step-Down Subsidiary
Mar 2, 2026
Aarti Drugs Limited has expanded its international footprint in the pharmaceutical sector through the incorporation of Tripharma Chile SpA as an overseas wholly owned subsidiary of its unit Pinnacle Chile SpA, making Tripharma a step-down subsidia...
Aarti Drugs Releases Q3 and 9M FY26 Investor Presentation
Feb 3, 2026
Aarti Drugs Limited has released its investor presentation for the third quarter and nine months of FY26, sharing detailed operational and financial updates with market participants. By making this presentation available to exchanges and investors...
Aarti Drugs Delivers Higher Profit on Modest Revenue Growth, Boosted by Value-Added Segments
Feb 3, 2026
Aarti Drugs Limited reported an 8% year-on-year rise in consolidated revenue to Rs 602.9 crore for the December 2025 quarter, while nine-month FY26 revenue grew 8% to Rs 1,846.6 crore, underscoring steady topline momentum. Despite a 10% YoY declin...
Aarti Drugs Schedules Q3 and Nine-Month FY26 Earnings Call with Investors
Jan 28, 2026
Aarti Drugs Limited has scheduled a quarterly earnings conference call with investors and analysts on 4 February 2026 to discuss its financial performance for the third quarter and nine months ended 31 December 2025. Senior management, including t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.